These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
143 related articles for article (PubMed ID: 20431561)
1. New drug approval success rate in Europe in 2009. Eichler HG; Aronsson B; Abadie E; Salmonson T Nat Rev Drug Discov; 2010 May; 9(5):355-6. PubMed ID: 20431561 [No Abstract] [Full Text] [Related]
2. European Medicines Agency pledges to publish clinical reports. Watson R BMJ; 2014 Oct; 349():g6086. PubMed ID: 25294699 [No Abstract] [Full Text] [Related]
3. European Medicines Agency-Health Technology Assessment Parallel Consultation Platform: An Industry Perspective. Khan S; Carter M Clin Pharmacol Ther; 2019 Apr; 105(4):822-825. PubMed ID: 30811582 [No Abstract] [Full Text] [Related]
4. EU court gets tough on patent extensions for combo products. Waters H Nat Med; 2012 Jan; 18(1):4. PubMed ID: 22227647 [No Abstract] [Full Text] [Related]
5. Regulatory science as a bridge between science and society. Tominaga T; Asahina Y; Uyama Y; Kondo T Clin Pharmacol Ther; 2011 Jul; 90(1):29-31. PubMed ID: 21691273 [TBL] [Abstract][Full Text] [Related]
7. New drug approvals for 2002. Frantz S; Smith A Nat Rev Drug Discov; 2003 Feb; 2(2):95-6. PubMed ID: 12572538 [No Abstract] [Full Text] [Related]
8. Researchers see a need for speed in EU trial approvals. Cressey D Nat Med; 2008 Aug; 14(8):794. PubMed ID: 18685580 [No Abstract] [Full Text] [Related]
9. Muddied messages about FDA. Miller HI Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084 [No Abstract] [Full Text] [Related]
10. Statisticians in European regulatory agencies. Skovlund E Pharm Stat; 2009; 8(4):259-63. PubMed ID: 19301357 [TBL] [Abstract][Full Text] [Related]
11. Expanded EU presents promise and challenges. Vermij P Nat Rev Drug Discov; 2004 May; 3(5):377-8. PubMed ID: 15152627 [No Abstract] [Full Text] [Related]
13. Industry concern over EU hepatotoxicity guidance. Hughes B Nat Rev Drug Discov; 2008 Sep; 7(9):719. PubMed ID: 19172685 [No Abstract] [Full Text] [Related]
14. Updated Manufacturer and European Medicines Agency Recommendations on the Use of Mycophenolate Acid: Balancing the Risks for Male Allograft Recipients. Kuypers DR; Van Mieghem T; Meijers B; Claes K Transplantation; 2016 Sep; 100(9):e50-1. PubMed ID: 27472093 [No Abstract] [Full Text] [Related]
15. The EMEA guideline on first-in-human clinical trials and its impact on pharmaceutical development. Milton MN; Horvath CJ Toxicol Pathol; 2009 Apr; 37(3):363-71. PubMed ID: 19246571 [No Abstract] [Full Text] [Related]
16. "Bonne Année", "Gutes Neues Jahr"? Will 2007 be a "Happy New Year" for children's medicines in Europe? Stephenson T Arch Dis Child; 2007 Aug; 92(8):661-3. PubMed ID: 17642477 [TBL] [Abstract][Full Text] [Related]
17. EMEA approves OGS drug rejected by FDA. Mitchell P Nat Biotechnol; 2002 Sep; 20(9):858-9. PubMed ID: 12205490 [No Abstract] [Full Text] [Related]
18. Pharmaceutical regulation in the European Community: barriers to single market integration. Orzack LH; Kaitin KI; Lasagna L J Health Polit Policy Law; 1992; 17(4):847-68. PubMed ID: 1299692 [TBL] [Abstract][Full Text] [Related]
19. Pharmaceuticals, the state and the global harmonisation process. Abraham J Aust Health Rev; 2004 Nov; 28(2):150-60. PubMed ID: 15527395 [TBL] [Abstract][Full Text] [Related]
20. Lessons from Eprex for biogeneric firms. Louët S Nat Biotechnol; 2003 Sep; 21(9):956-7. PubMed ID: 12949539 [No Abstract] [Full Text] [Related] [Next] [New Search]